Silicon Laboratories (SLAB) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to a loss of $0.08 per share a year ago.
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO, Dr Eric Leire, talked with Proactive about encouraging results from the SLAB (Sarcopenia and Longevity in Aged Beagles) trial, highlighting sustained efficacy and safety following treatment. Leire explained that one of the most significant findings is the durability of the therapy's effects.
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the European biotechnology company focused on gene therapies for age-related diseases, has reported that positive safety and efficacy signals from its SLAB trial have been maintained three months after the initial dosing period, with no adverse events observed. The SLAB (Sarcopenia and Longevity in Aged Beagles) trial is evaluating Genflow's proprietary SIRT6 centenarian gene therapy in aged dogs, targeting sarcopenia, the age-related loss of muscle mass and strength that also affects humans.
Silicon Labs (SLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Silicon Laboratories Inc. (SLAB) M&A Call Transcript
Texas Instruments Inc (NASDAQ:TXN) announced that it has agreed to acquire Silicon Laboratories (NASDAQ:SLAB) in an all-cash transaction valued at about $7.5 billion, expanding its presence in embedded wireless connectivity chips. Under the agreement, Silicon Labs shareholders will receive $231 per share in cash.
Texas Instruments has agreed to buy Silicon Labs for $7.5 billion. The announcement has skyrocketed Silicon Labs' stock price by nearly 50% in intraday.
Silicon Laboratories (SLAB) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to a loss of $0.11 per share a year ago.
Texas Instruments is in advanced talks to buy chip designer Silicon Laboratories for about $7 billion, the Financial Times reported on Tuesday.
Silicon Labs is capitalizing on IoT market growth, gaining share in Bluetooth and Wi-Fi, and outperforming peers despite not benefiting from AI/data center hype. SLAB's near-term growth is driven by smart metering, healthcare monitoring, and electronic shelf labeling, with a robust $10B design win pipeline supporting long-term prospects. Margins are set to improve with Series 3 product adoption and potential channel restocking, while management targets 20% annual revenue growth and 20%-plus operating margins.
Silicon Laboratories Inc. (SLAB) Presents at Barclays 23rd Annual Global Technology Conference Transcript
Silicon Laboratories (SLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.